NCT05987228

Brief Summary

Thymus vulgaris could potentially serve as a safer alternative to stimulant drugs for enhancing memory among university students. Furthermore, Thymus vulgaris may offer additional benefits in terms of reducing anxiety, depression, and improving sleep quality. However, it should be noted that the current research on the effects of orally administered Thymus vulgaris on the brain and nervous system is limited, and further studies are required to fully explore its potential advantages. Therefore, the purpose of this study is to investigate the effects of oral Thymus vulgaris on memory performance, anxiety, depression, and sleep quality in university students.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
86

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 1, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

August 14, 2023

Completed
Last Updated

August 14, 2023

Status Verified

August 1, 2023

Enrollment Period

4 months

First QC Date

August 1, 2023

Last Update Submit

August 9, 2023

Conditions

Memory DysfunctionAnxietyDepressionSleep

Keywords

Thymus vulgaris leavesMemory performanceAnxietyDepressionSleep

Outcome Measures

Primary Outcomes (1)

  • Memory performance

    Prospective and Retrospective Memory Questionnaire (PRMQ) was employed

    30 days

Secondary Outcomes (2)

  • Anxiety and depression

    30 days

  • Sleep quality

    30 days

Study Arms (2)

Thymus vulgaris group

EXPERIMENTAL

500 mg of Thymus vulgaris (capsules) was given orally twice daily

Dietary Supplement: Thymus vulgaris

control group

PLACEBO COMPARATOR

500 mg starch (capsules) was given orally twice daily

Dietary Supplement: Thymus vulgaris

Interventions

Thymus vulgarisDIETARY_SUPPLEMENT

500 mg of Thymus vulgaris (capsules) was given orally twice daily

Thymus vulgaris groupcontrol group

Eligibility Criteria

Age19 Years - 23 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Health participants

You may not qualify if:

  • individuals with medical diseases, psychiatric disorders, those using any medications (including complementary and alternative medicines), as well as pregnant and lactating individuals, were excluded from participating

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Pharmaceutical Sciences

Zarqa, 13133, Jordan

Location

MeSH Terms

Conditions

Anxiety DisordersDepression

Condition Hierarchy (Ancestors)

Mental DisordersBehavioral SymptomsBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisstant professor

Study Record Dates

First Submitted

August 1, 2023

First Posted

August 14, 2023

Study Start

August 1, 2022

Primary Completion

December 1, 2022

Study Completion

December 1, 2022

Last Updated

August 14, 2023

Record last verified: 2023-08

Locations

JO(1)